Jakub Dvořáček, CEO of the Czech Association of Innovative Pharmaceutical Industry (AIFP), describes the thorough review of the reimbursement…

A current lack of transparency in Czech healthcare spending is severely detrimental to all industry stakeholders. However, new synergies between the…

Mr. Dvořáček, in 2010, the AIFP commissioned a study on the economic footprint of the innovative pharmaceutical industry in the Czech Republic. Can…